Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus

Palma-Alvarez, Raul Felipe; Barta, Csaba; Carpentier, Pieter Jan; Carruthers, Susan; Crunelle, Cleo; Demetrovics, Zsolt; Ramos-Quiroga, Josep Antoni

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Palma-Alvarez, Raul Felipe
dc.contributor.author	Barta, Csaba
dc.contributor.author	Carpentier, Pieter Jan
dc.contributor.author	Carruthers, Susan
dc.contributor.author	Crunelle, Cleo
dc.contributor.author	Demetrovics, Zsolt
dc.contributor.author	Ramos-Quiroga, Josep Antoni
dc.date.accessioned	2023-11-17T08:36:47Z
dc.date.available	2023-11-17T08:36:47Z
dc.date.issued	2023-01
dc.identifier.citation	Palma-Álvarez RF, Barta C, Carpentier PJ, Carruthers S, Crunelle CL, Demetrovics Z, et al. Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. Span J Psychiatry Ment Heal. 2023 Jan-Mar;16(1):11–5.
dc.identifier.issn	2950-2853
dc.identifier.uri	https://hdl.handle.net/11351/10621
dc.description	Comorbidity; Psychometrics; Substance use disorder
dc.description.abstract	Objective This study aims to assess the validity of the ADHD module of the Mini-International Neuropsychiatric Interview (MINI-Plus) in patients with substance use disorders (SUD), using the Conners’ Adult ADHD Diagnostic Interview for DSM-IV (CAADID) as the external criterion. Method A cross sectional international multi-center study in 10 countries was conducted in treatment seeking SUD patients. A sample of 1263 patients with both MINI-Plus and CAADID was analyzed to determine the psychometric properties of the MINI-Plus. Results According to the CAADID, 179 patients (14.2%) met criteria for adult ADHD, whereas according to the MINI-Plus 227 patients (18.0%) were identified as having adult ADHD. Sensitivity of the MINI-Plus ADHD module was 74%, specificity was 91%, positive predictive value was 60% and negative predictive value was 96%. Kappa was 0.60. Conclusion The MINI-Plus has acceptable criterion validity for the screening of adult ADHD in treatment seeking SUD patients. Scientific significance On the basis of the results, The MINI-Plus may be used for the screening of ADHD in SUD patients.
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Spanish Journal of Psychiatry and Mental Health;16(1)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Trastorn per dèficit d'atenció amb hiperactivitat - Diagnòstic
dc.subject	Abús de substàncies
dc.subject	Malalties mentals
dc.subject	Tests neuropsicològics
dc.subject.mesh	Attention Deficit Disorder with Hyperactivity
dc.subject.mesh	/diagnosis
dc.subject.mesh	Substance-Related Disorders
dc.subject.mesh	Psychiatric Status Rating Scales
dc.title	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1016/j.rpsm.2020.04.013
dc.subject.decs	trastornos de déficit de atención con hiperactividad
dc.subject.decs	/diagnóstico
dc.subject.decs	trastornos relacionados con sustancias
dc.subject.decs	escalas de valoración psiquiátrica
dc.relation.publishversion	https://doi.org/10.1016/j.rpsm.2020.04.013
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Palma-Álvarez RF, Ramos-Quiroga JA] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Barta C] Institute of Medical Chemistry, Molecular Biology, Pathobiochemistry, Semmelweis University, Budapest, Hungary. [Carpentier PJ] Reinier van Arkel mental health institute, ‘s-Hertogenbosch, The Netherlands. [Carruthers S] National Drug Research Institute, Curtin University, Perth, Australia. [Crunelle CL] Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Toxicological Center, Antwerp University, Antwerp, Belgium. [Demetrovics Z] Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
dc.identifier.pmid	32561156
dc.rights.accessrights	info:eu-repo/semantics/openAccess